Compound Summary
Compound Information
化合物待补充
药名: | Tanshinone IIa |
别名: | SCHEMBL4126834; CHEMBL187266; UNII-4GPC9FQG6L; tanshinone II A; Phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; 568T729; BB_NC-1062; HMS1361P19; 17545-07-2; SCHEMBL2026738; CHEBI:108595; FT-0652880; AKOS004120032; MLS006011840; AC-1440; BSPBio_002426; HMS2270D15; SMR000387068; Acid Red 5 sodium salt; CT0134; Tanshinone IIA, >=97% (HPLC); NCGC00095755-03; Tanshinone IIA, United States Pharmacopeia (USP) Reference Standard; ACN-035345; CTK5A5836; Tanshinone IIA, analytical standard; AIDS-150197; s2365; NCGC00095709-01; HMS1791P19; CCG-208275; SC-17279; 1,6,6-Trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione-, (R)-; I06-0439; SR-01000758926-4; KBio3_000634; 1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dion; 6,6,14-trimethyl-12-oxatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1(10),2(7),8,11(15),13-pentaene-16,17-dione; Tanshinon II; AC1L4V8J; 4CN-0930; KBio2_000317; HSDB 8104; AN-14938; Tanshinone IIA; RTR-031585; BC205184; BRD-K00141480-001-03-0; AC1LAW3B; TL8003671; NCI60_031209; Phenanthro[1,2-b]furan-10,11-dione, 1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-, (R)-; 6,7,8,9-Tetrahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione; SMR004703500; CCG-207955; N1846; (?)-Cryptotanshinone; NCGC00095709-04; Phenanthro[1,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; Tanshinone II; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione #; HMS3656C11; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione; KBioSS_000317; SR-01000758926-2; MCULE-8689433740; NCGC00095709-03; I14-22013; Bio2_000317; NP474; NCGC00095709-02!TANSHINONE IIA; Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; BC678108; A831217; BBL010026; CTK8I3995; NSC686519; AS-16136; UPCMLD-DP042:001; KBioGR_000317; SBB066119; Dan Shen Ketone; STK801405; SR-01000758926-5; NSC-686519; S594; 1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g]benzofuran-10,11-dione; BG00628358; Ambotz568-72-9; MFCD00238692; Tanshinone A; InChI=1/C19H20O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,10H,4-5,8-9H2,1-3H3; BBL028449; Tanshinone B, Tanshinone II, 568-72-9; Tanshinone B; Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard; Cryptotanshinon; CHEMBL1518673; MLS001048863; STK801917; KBio2_005453; TR-031585; MolPort-002-507-310; AC1Q6JLQ; NCGC00095709-05; (-)-Cryptotanshinone; HMS3402P19; NCGC00095709-06; W-2832; SPECTRUM1505824; 4GPC9FQG6L; C19H18O3; Bio2_000797; HMS2089H08; Q-100654; Tanshinone IIa; Cryototanshinone; KBio2_002885; BDBM83922; IDI1_034067; 568-72-9; MLS006011834; BSPBio_001597; DTXSID60205352; GVKKJJOMQCNPGB-UHFFFAOYSA-; HYXITZLLTYIPOF-UHFFFAOYSA-N; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione; HMS1989P19; 6,6,14-trimethyl-12-oxatetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,7,9,11(15)-tetraene-16,17-dione; SR-01000758926; BIB6295; NCGC00095709-02; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione; cid_164676; ZINC01650576; NCGC00095755-01; MFCD05671363; GP2434; 1,6,6-trimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione; 6,6,14-trimethyl-12-oxatetracyclo[8.7.0.02,7.011,15]heptadeca-1(10),2(7),8,11(15),13-pentaene-16,17-dione; Tanshinone IIA (Tanshinone B); LS-175776; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g][1]benzoxole-10,11-dione; HMS3655P20; NSC 686518; I06-0645; tanshinone ii a; Tanshinone 2-A; KBio3_000633; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone; UPCMLD-DP042; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-quinone; AB0018692; NSC686518; AIDS150197; API0010219; GVKKJJOMQCNPGB-UHFFFAOYSA-N; STOCK1N-48169; HY-N0135; AKOS005612965; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione; TanshinoneIIA; ZINC1650576; 1,6,6-Trimethyl-1,2,6,7,8,9-hexahydrophenanthro[1,2-b]furan-10,11-dione; Neuro_000424 |
成分: | HBIN045506 |
OB_score: | 49.8873 |
CAS_id: | 568-72-9 |
SymMap_id: | SMIT00353;SMIT01680 |
TCMID_id: | 23205;20670 |
TCMSP_id: | MOL007154 |
PubChem_id: | 496348 |
化合物对应的植物
| 植物ID | 拉丁名 | 药用植物名 | 药名 | 来源 | 功能与主治 | 使用民族 |
|---|
| TCMBANKHE001548 | Salvia karabachensis | |||||
| TCMBANKHE001571 | Caulis Clematidis Armandii | 川木通 | To remove heat and induce diuresis, to stimulate menstrual discharge, and promote lactation./Treatment of edema, stranguria oliguria, arthralgia, amenorrhea, lack of lactation. | |||
| TCMBANKHE002149 | 楮实子 | |||||
| TCMBANKHE003752 | Radix Salviae liguliobae | 丹参 | To remove blood stasis and relieve pain, to promote the flow of blood and stimulate menstrual discharge, and to ease the mind./Angina pectoris, cerebral atherosclerosis, diffusive intravascular clotting, thrombophlebitis, hepatitis, acute surgical infection, mastitis, erysipelas, otitis media, tonsillitis, bone marrow infection, menstrual disorder, dysmenorrhea, amenorrhea, postpartum stasis stagnation abdominal pain, pain in heart and abdomen, concretion conglomeration accumulation and gathering, heat impediment swelling and pain, knocks and falls, heat entering construction-blood, vexation and agitation, insomnia and vexation, swelling toxin of welling abscess and sore, zoster, neurodermatitis, psoriasis. | |||
| TCMBANKHE003825 | Salvia prionitis | 红根草 | To course wind and clear heat, disinhibit damp, stanch bleeding, quiet fetus./Common cold with fever, pneumonia with cough and asthma, swelling pain in throat, hepatitis with rib-side pain, diarrhea, dysentery, nephritis, blood ejection, fetal spotting (precipitation of blood in pregnancy). | |||
| TCMBANKHE004486 | Salvia castanea | 栗色鼠尾草 | ||||
| TCMBANKHE005535 | Salvia sinica | 丹蔘 | ||||
| TCMBANKHE007760 | Salvia sclarea | 南欧丹参 | ||||
| TCMBANKHE008921 | Salvia miltiorrhiza f. alba | 白花丹参 | See Salvia miltiorrhiza ./See Salvia miltiorrhiza. | |||
| TCMBANKHE008493 | Veronicastrum sibiricum | 斩龙剑 | To clear heat and resolve toxin, dispel wind and eliminate damp, relieve pain./Wind-damp pain in lumbus and legs, courbature, common cold, cystitis, tuberculosis, bleeding due to external injury, poisonous snake bite, poisonous insect stings. | |||
| TCMBANKHE007898 | Salvia bowleyana | 南丹参 | To quicken blood and transform stasis, regulate menstruation and relieve pain./Chest impediment and angina, vexation, heart palpitation, pain in stomach duct and abdomen, menstrual disorder [=menoxenia], menstrual pain, menstrual block, postpartum stasis stagnation abdominal pain, flooding and spotting, liver spleen enlargement, arthralgia, mounting qi (hernia), swelling of sores. | |||
| TCMBANKHE008746 | Salvia bulleyana | 戟叶鼠尾草;基业鼠尾草 | ||||
| TCMBANKHE008512 | radix Peucedani | 前胡 | To dispel wind and remove heat, and to relieve cough and resolve phlegm ./Cough, externally contracted wind-heat, lung heat phlegm depression, cough and asthma with abundant phlegm, sticky phlegm, retching counterflow and reduced food intake, fullness and oppression in chest and diaphragm. | |||
| TCMBANKHE008720 | 鼠尾草 | |||||
| TCMBANKHE006416/YEM-113 | Salvia digitaloides|Salvia digitaloides Diels | 毛地黄鼠尾草|毛地黄鼠尾 | 毛地黄鼠尾 | 云南民族药物志：第一卷 | To quicken blood and dispel stasis, disinhibit damp and resolve toxin./Chest impediment and angina, menstrual disorder, menstrual pain, vaginal protrusion (prolapse of uterus), flooding and spotting, red and white vaginal discharge, malign sore and swelling toxin. | 纳西族 |
| TCMBANKHE008854/YNS-329/YEM-33/XU-201 | Salvia yunnanensis|Salvia yunnanensis C.H.Wright.|Salvia yunnanensis C.H.Wright | 云南鼠尾草|滇丹参 | 紫丹参|滇丹参 | 云南药材标准：第一册|云南民族药物志：第一卷|曲靖市会泽县待补镇 | 活血调经，祛瘀止痛，清心除烦。用于月经不调，经闭痛经，癥瘕积聚，胸腹刺痛，热痹疼痛，心烦不眠，痈肿疮毒。|To quicken blood and dispel stasis, cool blood and stanch bleeding, nourish heart and quiet spirit, resolve toxin and disperse swelling./Menstrual disorder, dysmenorrhea, menstrual block, persistent flow with abdominal pain, concretion and conglomeration, chest impediment and angina, arthralgia, mounting qi (hernia), flooding and spotting, blood ejection, spontaneous external bleeding, hacking of blood, blood vacuity and numbness in limbs, sleepless, amnesia, fright palpitation, fearful throbbing, mammary welling abscess, swelling of sores, stasis swelling from knocks and falls. | 彝族 |
| TCMBANKHE005432/YNS-47/YEM-51/XU-527 | Salvia przewalskii|Salvia przewalskii Maxim.var.mandarinorum(Diels) Stib.|Salvia przewalskii Maxim. | 甘西鼠尾草|褐毛甘西鼠尾|甘西鼠尾 | 大紫丹参|甘西鼠尾 | 云南药材标准：第七册|云南民族药物志：第一卷|西藏昌都市芒康县 | 活血化瘀，通经止痛，清心安神。用于胸痹心痛，心烦失眠，脘腹胁痛，痛经、经闭、产后恶露不尽，风湿痹痛，癥瘕，疮疡肿痛。|See Salvia miltiorrhiza ./See Salvia miltiorrhiza . | 彝族/藏族 |
| TCMBANKHE004164/YNS-47/YEM-51/XU-527 | Salvia przewalskii var. mandarinorum|Salvia przewalskii Maxim.var.mandarinorum(Diels) Stib.|Salvia przewalskii Maxim.|Salvia przewalskii | 紫丹参|褐毛甘西鼠尾|甘西鼠尾|甘西鼠尾草 | 大紫丹参|甘西鼠尾 | 云南药材标准：第七册|云南民族药物志：第一卷|西藏昌都市芒康县 | 活血化瘀，通经止痛，清心安神。用于胸痹心痛，心烦失眠，脘腹胁痛，痛经、经闭、产后恶露不尽，风湿痹痛，癥瘕，疮疡肿痛。 | 彝族/藏族 |
| TCMBANKHE008681/YEM-541 | Salvia flava|Salvia flava Forr. | 黄花鼠尾草|黄花鼠尾 | 黄花鼠尾 | 云南民族药物志：第三卷 | To quicken blood and regulate menstruation, transform stasis and relieve pain./Menstrual disorder, menstrual pain, menstrual block, flooding and spotting, blood ejection, wind-damp bone pain, mammary welling abscess, swelling of sores. | 藏族 |
| TCMBANKHE008754/YEM-818 | Salvia trijuga|Salvia trijuga Diels | 三叶鼠尾草 | 三叶鼠尾 | 云南民族药物志：第四卷 | To quicken blood and regulate menstruation, dispel stasis and engender flesh, boost kidney and quiet spirit./Menstrual disorder, dysmenorrhea, menstrual block, flooding, kidney vacuity lumbago, impotence, insomnia, frequent dreaming, knocks and falls. | 藏族 |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
化合物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 |
|---|
| TCMBANKGE000142 | CALCR | CRT; CT-R; CTR; CTR1 | calcitonin receptor |
| TCMBANKGE000181 | PIM1 | PIM | Pim-1 proto-oncogene, serine/threonine kinase |
| TCMBANKGE000201 | ESR1 | ER; ESR; ESRA; ESTRR; Era; NR3A1 | estrogen receptor 1 |
| TCMBANKGE000205 | NOS2 | HEP-NOS; INOS; NOS; NOS2A | nitric oxide synthase 2 |
| TCMBANKGE000222 | EDN1 | ARCND3; ET1; HDLCQ7; PPET1; QME | endothelin 1 |
| TCMBANKGE000286 | GSK3B | - | glycogen synthase kinase 3 beta |
| TCMBANKGE000294 | CDKN1A | CAP20; CDKN1; CIP1; MDA-6; P21; SDI1; WAF1; p21CIP1 | cyclin dependent kinase inhibitor 1A |
| TCMBANKGE000309 | SCN5A | CDCD2; CMD1E; CMPD2; HB1; HB2; HBBD; HH1; ICCD; IVF; LQT3; Nav1.5; PFHB1; SSS1; VF1 | sodium voltage-gated channel alpha subunit 5 |
| TCMBANKGE000313 | JUN | AP-1; AP1; c-Jun; cJUN; p39 | Jun proto-oncogene, AP-1 transcription factor subunit |
| TCMBANKGE000360 | CCNA2 | CCN1; CCNA | cyclin A2 |
| TCMBANKGE000425 | DRD1 | DADR; DRD1A | dopamine receptor D1 |
| TCMBANKGE000474 | NCOA1 | F-SRC-1; KAT13A; RIP160; SRC1; bHLHe42; bHLHe74 | nuclear receptor coactivator 1 |
| TCMBANKGE000478 | CHEK1 | CHK1 | checkpoint kinase 1 |
| TCMBANKGE000633 | ADRB2 | ADRB2R; ADRBR; B2AR; BAR; BETA2AR | adrenoceptor beta 2 |
| TCMBANKGE000701 | ESR2 | ER-BETA; ESR-BETA; ESRB; ESTRB; Erb; NR3A2; ODG8 | estrogen receptor 2 |
| TCMBANKGE000766 | ACHE | ACEE; ARACHE; N-ACHE; YT | acetylcholinesterase (Cartwright blood group) |
| TCMBANKGE000813 | DPP4 | ADABP; ADCP2; CD26; DPPIV; TP103 | dipeptidyl peptidase 4 |
| TCMBANKGE000857 | AHSA1 | AHA1; C14orf3; hAha1; p38 | activator of HSP90 ATPase activity 1 |
| TCMBANKGE000867 | ITGB3 | BDPLT16; BDPLT2; CD61; GP3A; GPIIIa; GT | integrin subunit beta 3 |
| TCMBANKGE000898 | MYC | MRTL; MYCC; bHLHe39; c-Myc | MYC proto-oncogene, bHLH transcription factor |
| TCMBANKGE000938 | CDK2 | CDKN2; p33(CDK2) | cyclin dependent kinase 2 |
| TCMBANKGE000965 | CHRNA7 | CHRNA7-2; NACHRA7 | cholinergic receptor nicotinic alpha 7 subunit |
| TCMBANKGE000970 | FASN | FAS; OA-519; SDR27X1 | fatty acid synthase |
| TCMBANKGE001007 | NR1I2 | BXR; ONR1; PAR; PAR1; PAR2; PARq; PRR; PXR; SAR; SXR | nuclear receptor subfamily 1 group I member 2 |
| TCMBANKGE001008 | CYP3A4 | CP33; CP34; CYP3A; CYP3A3; CYPIIIA3; CYPIIIA4; HLP; NF-25; P450C3; P450PCN1 | cytochrome P450 family 3 subfamily A member 4 |
| TCMBANKGE001073 | PTGS2 | COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2 | prostaglandin-endoperoxide synthase 2 |
| TCMBANKGE001079 | CYP1A1 | AHH; AHRR; CP11; CYP1; CYPIA1; P1-450; P450-C; P450DX | cytochrome P450 family 1 subfamily A member 1 |
| TCMBANKGE001098 | NFKBIA | EDAID2; IKBA; MAD-3; NFKBI | NFKB inhibitor alpha |
| TCMBANKGE001118 | MMP9 | CLG4B; GELB; MANDP2; MMP-9 | matrix metallopeptidase 9 |
| TCMBANKGE001156 | CASP3 | CPP32; CPP32B; SCA-1 | caspase 3 |
| TCMBANKGE001166 | BCL2 | Bcl-2; PPP1R50 | BCL2 apoptosis regulator |
| TCMBANKGE001171 | SRC | ASV; SRC1; THC6; c-SRC; p60-Src | SRC proto-oncogene, non-receptor tyrosine kinase |
| TCMBANKGE001177 | TP53 | BCC7; BMFS5; LFS1; P53; TRP53 | tumor protein p53 |
| TCMBANKGE001184 | RELA | CMCU; NFKB3; p65 | RELA proto-oncogene, NF-kB subunit |
| TCMBANKGE001197 | FOS | AP-1; C-FOS; p55 | Fos proto-oncogene, AP-1 transcription factor subunit |
| TCMBANKGE001202 | MAPK14 | CSBP; CSBP1; CSBP2; CSPB1; EXIP; Mxi2; PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA | mitogen-activated protein kinase 14 |
| TCMBANKGE001450 | ECE1 | ECE | endothelin converting enzyme 1 |
| TCMBANKGE001943 | ADRA1D | ADRA1; ADRA1A; ADRA1R; ALPHA1; DAR; dJ779E11.2 | adrenoceptor alpha 1D |
| TCMBANKGE003157 | CHRM2 | HM2 | cholinergic receptor muscarinic 2 |
| TCMBANKGE004266 | AR | AIS; AR8; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM | androgen receptor |
| TCMBANKGE005535 | CHRM1 | HM1; M1; M1R | cholinergic receptor muscarinic 1 |
| TCMBANKGE006943 | CHRM3 | EGBRS; HM3; PBS | cholinergic receptor muscarinic 3 |
| TCMBANKGE006949 | PARP4 | ADPRTL1; ARTD4; PARP-4; PARPL; PH5P; VAULT3; VPARP; VWA5C; p193 | poly(ADP-ribose) polymerase family member 4 |
| TCMBANKGE008702 | OPRM1 | LMOR; M-OR-1; MOP; MOR; MOR1; OPRM | opioid receptor mu 1 |
| TCMBANKGE008921 | RXRA | NR2B1 | retinoid X receptor alpha |
| TCMBANKGE009455 | CHRM5 | HM5 | cholinergic receptor muscarinic 5 |
| TCMBANKGE011881 | NPM1 | B23; NPM | nucleophosmin 1 |
| TCMBANKGE011923 | CHRM4 | HM4; M4R | cholinergic receptor muscarinic 4 |
| TCMBANKGE013860 | EDNRA | ET-A; ETA; ETA-R; ETAR; ETRA; MFDA; hET-AR | endothelin receptor type A |
| TCMBANKGE014625 | OPRD1 | DOP; DOR; DOR1; OPRD | opioid receptor delta 1 |
| TCMBANKGE015090 | CYP1A2 | CP12; CYPIA2; P3-450; P450(PA) | cytochrome P450 family 1 subfamily A member 2 |
滇ICP备16009434号-1 |
Dai SX Lab